Find It Early Act
- Sponsor
- Sen. Klobuchar, Amy [D-MN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Apr 10, 2025
Bottom line
The bill aims to improve early breast cancer detection for at-risk individuals by eliminating financial barriers to advanced screening methods across major public and private health programs.
What it actually does
This bill mandates that private health insurance plans, Medicare, Medicaid, TRICARE, and the Department of Veterans Affairs cover additional breast cancer screenings with no cost-sharing for individuals at increased risk of breast cancer, those with dense breast tissue, or those determined by a healthcare provider to require such screenings due to other factors. It specifies that these screenings can include 2D or 3D mammograms, breast ultrasounds, breast magnetic resonance imaging, and molecular breast imaging, without limitation on frequency.
Proponents argue
Proponents argue that early detection of breast cancer is crucial for improving patient outcomes and survival rates. They contend that current screening guidelines and coverage may not be sufficient for individuals at higher risk or with dense breast tissue, who often require more advanced or frequent screenings. Eliminating cost-sharing will remove financial barriers, ensuring that all eligible individuals can access these potentially life-saving diagnostic tools.
Opponents contend
Opponents may raise concerns about the potential for increased healthcare costs, which could lead to higher insurance premiums for private plans and increased federal expenditures for public programs. Some might also argue about the potential for over-screening, leading to false positives, unnecessary follow-up procedures, and increased patient anxiety, without a clear demonstration of improved overall health outcomes for all covered populations.
The bill is concise and clearly structured, making it accessible for an informed reader to understand its core provisions within the time given.
Section 2(a)(1) & (2)
Expanded Coverage for Private Health Plans
This provision amends the Public Health Service Act to require group health plans and health insurance coverage to provide coverage with no cost-sharing for additional breast cancer screenings. This applies to individuals at increased risk, those with dense breast tissue, or those whose healthcare provider determines they need such screenings due to factors like age, race, ethnicity, or family history. The coverage includes various advanced imaging technologies and applies to plan years starting January 1, 2026.
Supporters argue
Supporters argue this ensures equitable access to critical screenings for those most at risk, aligning private insurance with best medical practices and potentially saving lives through earlier detection.
Critics contend
Critics may contend that this mandate increases the cost of private health insurance, potentially leading to higher premiums for all policyholders, without necessarily demonstrating a proportional benefit for every individual.
Tradeoffs
The provision balances the public health benefit of expanded screening access against the potential for increased healthcare costs and insurance premiums.
Section 2(a)(3)
Application to Grandfathered Health Plans
This section amends the Patient Protection and Affordable Care Act to ensure that the new mandate for breast cancer screening coverage with no cost-sharing also applies to 'grandfathered' health plans. Grandfathered plans are typically exempt from certain ACA requirements, but this provision specifically includes them under the new screening mandate.
Section 2(b)
Expanded Coverage Under Medicare
This provision amends the Social Security Act to include expanded breast cancer screening and diagnostic imaging with no limitation on frequency under Medicare. This applies to individuals at increased risk, those with dense breast tissue, or those determined by a healthcare provider to require such screenings. The coverage includes various advanced imaging technologies and takes effect on January 1, 2026, also applying no cost-sharing under Medicare Advantage plans.
Section 2(c)
Expanded Coverage Under Medicaid
This provision amends the Social Security Act to require Medicaid programs to cover additional breast cancer screening and diagnostic imaging with no limitation on frequency and no cost-sharing. This applies to individuals at increased risk, those with dense breast tissue, or those determined by a healthcare provider to require such screenings. The coverage includes various advanced imaging technologies and takes effect on January 1, 2026, with a potential delay for states requiring legislative action.
Section 2(d)
Expanded Coverage Under TRICARE
This provision amends Title 10 of the U.S. Code to expand coverage and eliminate cost-sharing for additional breast cancer screenings under TRICARE. This applies to uniformed service members and their beneficiaries who are at increased risk, have dense breast tissue, or are determined by a healthcare provider to require such screenings. The coverage includes various advanced imaging technologies and takes effect on January 1, 2026.
Section 2(e)
Expanded Coverage for Veterans Affairs (VA)
This provision amends Title 38 of the U.S. Code, directing the Secretary of Veterans Affairs to furnish additional breast cancer screenings with no cost-sharing to eligible veterans. This applies to veterans at increased risk, those with dense breast tissue, or those determined by a healthcare provider to require such screenings, regardless of their enrollment status in the VA's annual patient enrollment system. The coverage includes various advanced imaging technologies and takes effect on January 1, 2026.
The bill explicitly applies the new coverage mandate for breast cancer screenings to 'grandfathered health plans' by amending Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act.
Section 2(a)(3)
Why it matters:This is standard legislative practice for ensuring comprehensive application of new mandates across different types of health plans, rather than an attempt to obscure the provision. Grandfathered plans are a distinct category that often requires specific inclusion.
Case for: Supporters argue that including grandfathered plans ensures that all individuals, regardless of their specific plan type, receive the same essential screening benefits, preventing a two-tiered system of care.
Case against: Critics of mandates on grandfathered plans argue it erodes the original intent of allowing these plans to maintain their existing structure, potentially forcing changes that increase costs for employers and individuals who chose these plans.
Estimated impact: Ensures that a significant number of individuals covered by grandfathered plans will also benefit from no-cost advanced breast screenings.
For Medicaid, the effective date of January 1, 2026, can be delayed in states where new state legislation (other than appropriations) is required to implement the changes. The delay can extend until the first calendar quarter after the close of the first regular legislative session that ends after a one-year period from the bill's enactment.
Section 2(c)(4)(B)
Why it matters:This is a common and practical legislative mechanism to accommodate state legislative cycles, allowing states sufficient time to adapt their laws to federal mandates. It is not intended to be evasive.
Case for: Proponents argue this flexibility is essential for states to comply with federal mandates without disrupting their legislative processes, ensuring smoother implementation and avoiding legal challenges.
Case against: Critics might argue that such delays could create temporary inequities in access to care, where beneficiaries in some states receive expanded coverage sooner than those in others, undermining the immediate national impact of the bill.
Estimated impact: Could result in a staggered implementation of expanded Medicaid breast cancer screening coverage across different states, potentially delaying benefits for some beneficiaries by up to two years.
The criteria for determining 'increased risk of breast cancer' or 'heterogeneously or extremely dense breast tissue' are defined by external medical standards: the American College of Radiology Appropriateness Criteria, the National Comprehensive Cancer Network guidelines, and the Breast Imaging Reporting and Data System.
Multiple sections (e.g., 2(a)(1)(E)(i), 2(b)(1)(B)(ii), 2(c)(1)(G)(i))
Why it matters:This is a common legislative technique to ensure that medical coverage decisions are based on evolving scientific and clinical consensus, rather than being static within the law. It allows for flexibility as medical understanding advances.
Case for: Proponents argue that referencing external, regularly updated medical guidelines ensures that coverage remains aligned with the latest evidence-based practices, providing the most effective and appropriate care.
Case against: Critics might argue that relying on external guidelines delegates significant authority to non-governmental bodies, potentially leading to changes in coverage scope and cost without direct congressional oversight or public debate.
Estimated impact: The scope and cost of the expanded coverage will dynamically adjust over time as medical guidelines evolve, potentially broadening or narrowing the eligible population and covered technologies.